CCR5 promoter polymorphism determines macrophage CCR5 density and magnitude of HIV-1 propagation in vitro - PubMed (original) (raw)
Comparative Study
CCR5 promoter polymorphism determines macrophage CCR5 density and magnitude of HIV-1 propagation in vitro
Janelle R Salkowitz et al. Clin Immunol. 2003 Sep.
Abstract
The common CCR5 promoter polymorphism at position -2459 (A/G) has been associated with differences in the rate of progression to AIDS, where HIV-1-infected individuals with the CCR5 -2459 G/G genotype exhibit slower disease progression than those with the A/A genotype. Mechanisms underlying the relationship between these polymorphisms and disease progression are not known. Here through in vitro infection of peripheral blood mononuclear cells obtained from healthy Caucasian blood donors with macrophage-tropic HIV-1 isolates we observed low, medium, and high viral propagation in association with G/G, A/G, and A/A promoter genotypes, respectively. Flow cytometric analysis of unstimulated CD14+ monocytes from these same donors revealed a similar hierarchy of CCR5 receptor density in association with promoter genotypes. Finally, PBMC from persons with the G/G promoter polymorphism produced higher levels of beta-chemokines after in vitro stimulation. Thus, the CCR5 -2459 (A/G) promoter polymorphism determines CCR5 expression and predicts the magnitude of HIV-1 propagation in vitro. These findings may provide important insight regarding the regulation of mechanisms that influence the rate of HIV-1 propagation and progression to AIDS.
Figures
Fig. 1
CCR5 expression on CD14+ monocytes. The number of chemokine receptors/cell from 16 uninfected Caucasian blood donors is shown on the y axis. The number of G/G (△) and A/G (○) donors were 10 (4 and 6, respectively), and the number of A/A donors was 6 (□).
Fig. 2
CCR5 –2459 SNP and in vitro infection with R5-tropic HIV-1 isolate JR-FL. Magnitude of HIV-1 p24 antigen produced (y axis) over time (x axis). (A) Suboptimal stimulation of PBMC obtained from four people with the G/G genotype (○) produced on average 1.2 ± 1.7 (mean ± SE) ng HIV-1 p24 antigen/ml, PBMC obtained from six people with the A/G genotype (▽) produced on average 15.7 ± 12.8 ng/p24 antigen/ml, PBMC obtained from five people with the A/A genotype (□) produced on average 109 ± 105.7 ng/ml (P < 0.05, Kruskall–Wallis test). (B) Near-optimal stimulation of PBMC from persons with the G/G genotype produced 54.3 ± 34.6 ng p24 antigen/ml; A/G PBMC produced 61 ± 40.3 ng/ml; A/A PBMC produced 131 ± 90.2 ng/ml (P < 0.7, Kruskal–Wallis test) over 11 days in culture.
Fig. 3
CCR5 (–)2459 SNP and supernatant β_-chemokine production. In vitro production of β_-chemokines at near-optimal stimulation conditions: (A). MIP-1_α, (B) MIP-1_β, and (C) RANTES. The number of G/G donors was 5, A/G donors was 7, and A/A donors was 6.
Similar articles
- Chemokine receptor gene polymorphisms and COVID-19: Could knowledge gained from HIV/AIDS be important?
Mehlotra RK. Mehlotra RK. Infect Genet Evol. 2020 Nov;85:104512. doi: 10.1016/j.meegid.2020.104512. Epub 2020 Aug 26. Infect Genet Evol. 2020. PMID: 32858232 Free PMC article. Review. - CCR5 genotype and plasma beta-chemokine concentration of Brazilian HIV-infected individuals.
Mikawa AY, Tagliavini SA, Costa PI. Mikawa AY, et al. Braz J Med Biol Res. 2002 Nov;35(11):1333-7. doi: 10.1590/s0100-879x2002001100011. Braz J Med Biol Res. 2002. PMID: 12426633 - Inhibition of HIV-1 replication by GB virus C infection through increases in RANTES, MIP-1alpha, MIP-1beta, and SDF-1.
Xiang J, George SL, Wünschmann S, Chang Q, Klinzman D, Stapleton JT. Xiang J, et al. Lancet. 2004 Jun 19;363(9426):2040-6. doi: 10.1016/S0140-6736(04)16453-2. Lancet. 2004. PMID: 15207954 - Heterozygous defect in HIV-1 coreceptor CCR5 and chemokine production.
Yang JY, Togni M, Widmer U. Yang JY, et al. Cytokine. 1999 Jan;11(1):1-7. doi: 10.1006/cyto.1998.0396. Cytokine. 1999. PMID: 10080873 - Genetics of HIV-1 infection: chemokine receptor CCR5 polymorphism and its consequences.
Carrington M, Dean M, Martin MP, O'Brien SJ. Carrington M, et al. Hum Mol Genet. 1999;8(10):1939-45. doi: 10.1093/hmg/8.10.1939. Hum Mol Genet. 1999. PMID: 10469847 Review.
Cited by
- Reduced CCR5 expression among Uganda HIV controllers.
Nyiro B, Amanya SB, Bayiyana A, Wasswa F, Nabulime E, Kayongo A, Nankya I, Mboowa G, Kateete DP, Sande OJ. Nyiro B, et al. Retrovirology. 2023 May 25;20(1):8. doi: 10.1186/s12977-023-00626-7. Retrovirology. 2023. PMID: 37231494 Free PMC article. - The Influence Between C-C Chemokine Receptor 5 Genetic Polymorphisms and the Type-1 Human Immunodeficiency Virus: A 20-Year Review.
Santana DS, Silva MJA, de Marin ABR, Costa VLDS, Sousa GSM, de Sousa JG, Silva DC, da Cruz EC, Lima LNGC. Santana DS, et al. AIDS Res Hum Retroviruses. 2023 Jan;39(1):13-32. doi: 10.1089/AID.2022.0111. Epub 2022 Nov 9. AIDS Res Hum Retroviruses. 2023. PMID: 36226448 Free PMC article. Review. - Understanding Viral and Immune Interplay During Vertical Transmission of HIV: Implications for Cure.
Amin O, Powers J, Bricker KM, Chahroudi A. Amin O, et al. Front Immunol. 2021 Oct 21;12:757400. doi: 10.3389/fimmu.2021.757400. eCollection 2021. Front Immunol. 2021. PMID: 34745130 Free PMC article. Review. - A Polymorphism in C-C Chemokine Receptor 5 (CCR5) Associates with Löfgren's Syndrome and Alters Receptor Expression as well as Functional Response.
Karakaya B, van Moorsel CHM, Veltkamp M, Roodenburg-Benschop C, Kazemier KM, van der Helm-van Mil AHM, Huizinga TWJ, Grutters JC, Rijkers GT. Karakaya B, et al. Cells. 2021 Aug 3;10(8):1967. doi: 10.3390/cells10081967. Cells. 2021. PMID: 34440736 Free PMC article. - Chemokine receptor gene polymorphisms and COVID-19: Could knowledge gained from HIV/AIDS be important?
Mehlotra RK. Mehlotra RK. Infect Genet Evol. 2020 Nov;85:104512. doi: 10.1016/j.meegid.2020.104512. Epub 2020 Aug 26. Infect Genet Evol. 2020. PMID: 32858232 Free PMC article. Review.
References
- Zhu T, Mo H, Wang N, Nam DS, Cao Y, Koup RA, Ho DD. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science. 1993;261:1179. - PubMed
- Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, Goedert JJ, Buchbinder SP, Vittinghoff E, Gomperts E, Donfield S, Vlahov Kaslow D, Saah A, Rinaldo C, Detels R. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CCR5 structural gene. Science. 1996;273:1856. - PubMed
- Huang Y, Paxton WA, Wolinsky SM, Neumann AU, Zhang L, He T, Kang S, Ceradini D, Jin Z, Yazdanbakhsh K, Kunstman K, Erickson D, Dragon E, Landau N, Phair J, Ho DD, Koup R. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med. 1996;2 - PubMed
- O’Brien TR, Winkler C, Dean M, Nelson JA, Carrington M, Michael NL, White GC., 2nd HIV-1 infection in a man homozygous for CCR5 delta 32. Lancet. 1997;349:1219. [letter] [see comments] - PubMed
- Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, Saragosti S, Lapoumeroulie C, Cognaux J, Forceille C, Muyldermans G, Verhofstede C, Burtonboy G, Georges M, Imai T, Rana S, Yi Y, Smyth RJ, Collman RG, Doms RW, Vassart G, Parmentier M. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature. 1996;382:722. [see comments] - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P01 AI051649/AI/NIAID NIH HHS/United States
- AI 36219/AI/NIAID NIH HHS/United States
- AI 51649/AI/NIAID NIH HHS/United States
- AI 43645/AI/NIAID NIH HHS/United States
- P30 AI036219/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Research Materials